Lupin shares took a hit after the United States Food and Drug Administration (USFDA) issued three critical observations regarding its Pithampur Unit-1 facility. On September 30, 2024, Lupin's stock dropped by 2.26%, reaching an intraday low of ₹2,171.25 per share.
Impact of USFDA observations
The USFDA inspected Lupin’s Pithampur Unit-1, Madhya Pradesh, from September 16 to 27, 2024. Following the inspection, three observations were made regarding both the active pharmaceutical ingredient (API) and finished product segments. While the company is working on a detailed response to address these concerns, the market reaction was immediate.
Investors looking to buy shares online need to keep in mind how regulatory actions, such as USFDA inspections, can impact stock prices in the pharmaceutical sector. Lupin clarified that they would respond to the USFDA within the stipulated timeframe, which could alleviate some investor concerns.
Financial performance of Lupin
Despite the recent drop, Lupin's financial performance has been strong. In the June quarter of FY25, Lupin posted a 77.2% year-on-year increase in profit after tax (PAT), amounting to ₹801 crore. Revenue also grew by 16.2% year-on-year to ₹5,514.3 crore, showcasing steady growth. On a sequential basis, the company’s PAT grew by 122.9%, and revenue saw a 12.6% rise.
For those interested in buying shares online, it’s essential to consider both short-term regulatory impacts and long-term financial health before making investment decisions.
Lupin’s stock performance over time
Despite the recent regulatory setback, Lupin shares have performed well over the long term. The stock has surged over 65% year-to-date and has risen by over 85% in the past year. However, in the last month, Lupin’s shares have fallen by approximately 2%, with a 0.7% decline over the past five days.
For investors who regularly buy shares online, keeping an eye on Lupin’s regulatory updates and financials will provide a clearer perspective on whether this dip presents a buying opportunity or warrants caution.
Invest safely
The recent USFDA observations have caused a temporary setback for Lupin’s stock, leading to a 2.26% drop. However, with the company’s strong financials and its commitment to addressing the USFDA concerns, investors may view this as a short-term issue. As always, those looking to buy shares online should weigh the risks and rewards, considering both regulatory impacts and long-term performance before making investment decisions.
The stock market can be unpredictable, but informed decisions based on comprehensive research can help investors navigate such volatility.
For android only